<DOC>
<DOCNO>EP-0200024</DOCNO> 
<TEXT>
<INVENTION-TITLE>
3-CYANO-PYRIDINES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D40700	C07D40714	C07D21385	C07D21300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D407	C07D407	C07D213	C07D213	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
3-Cyanopyridines substituted in the 2-position by oxaalkylamino, aminoalkylamino or oxaalkoxy groups and containing pyridyl or phenyl radicals in the 5-position have cardiotonic, antiarrhythmic, vasodilatory, bronchodilatory and antiallergic effects.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>

 Neue 3-Cyan-pyridine, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung Die Erfindung betrifft neue 3-Cyan-pyridine der Formel I, in der R1 für Oxaalkylamino, Aminoalkylamino, Oxaalkyloxy, Acyloxyalkylamino, Acylaminoalkoxylamino der Acyloxyalkyloxy, Rê für Pyrid-4-yl, Phenyl sowie alkyloxyliertes Phenyl und R3 für H oder Methyl stehen können, ihre physiologisch verträglichen säureadditionsalze, Verfahren zur Herstellung der neuen Verbindungen und ibre pharmazeutische Verwendung.
EMI1.1     
  


Die neuen Verbindungen, auch in Form ihrer physiologisch verträglichen Säureadditionssalze, zeigen kardiotonische, antiarrhythmische, vasodilatatorische, bronchodilatatorische bzw. antiallergische Wirkungen.


6-unsubstituierte sowie 6-alkylsubstituierte 3-Cyan-5 (pyrid-4-yl)-1,2-dihydro-pyrid-2-one und ihre kardiotonische Wirkung sind beschrieben (s. z.B. G.Y.   Bester    et al., US-PS 4   0Q4    012, US-PS 4 199 586 und US-PS 4 264 609; G.Y. Lesher et al., US-PS 4313 951, B. Singh, US-PS   4:    347 363, US-PS 4 413 127. EP-PS   75    11.6; K.O. Gelotte US-PS 4 417 054).


Bekannt sind auch kardiotonisch wirksame   5-Aryl-3-cyan-    6-methyl-1,2-dihydro-pyrid-2-one (G.Y. Lesher et al., US-PS   4 465    686, EP-PS 061 774,   E?-PS    74 091; G. Bormann, GB-PS 2 070 606, BE-PS 896 678, DE-PS 3   106    460, DE-PS 3 317 289).


Beschrieben worden sind weiter 6-unsubstituierte und 6-alkylsubstituierte 3-Cyan-2-ethylamino- bzw. 3-Cyan2-methylamino-5-pyridyl-pyridine (G.Y. Lesher et al., US-PS 4 362 734) sowie 2-Methoxy- und 2-Ethoxy-3-cyan- 5-pyridyl-pyridiny [P. Natka-Namirski et al., Pol.


J. Pharmacol. Pharm 30 (1978), 707, G.Y. Lesher et a US-PS 4 463 008]. Ebenfalls bekannt ist 2-Amino-3cyan-6-methyl-5-phenyl-pyridin (J.L. Miesel, US-PS 4 405 552, EP-PS 60 071).


Beschrieben sind auch 3-Amino-   (bzw.      3-Nitro-' bzw.   


3-Carbamido-)2-(hersteraalkylamino)-5-(pyrid-4-yl)-pyridine   (G.Y.    Lesher et   -al.,    US-PS 4 297 360, US-PS 4 374   141',    GB-PS 2 073 185, DE-PS 3 112 251).  


Bekannt sind das 6-unsubstituierte und das 6-methylsubstituierte   2-Chlor-3-cyan-5-(pyrid-4-yl)-pyridin    (s.   z.B.   


   G.Y.    Lesher et al., US-PS 4 264 603) sowie 2-Chlor-3cyan-6-methyl-5-phenyl-pyridin   EM.    Julia et al.,   Bull.   


Soc. Chim. France 76 (1966), 2387].


3-Cyan-2-oxaalkylamino-, 3-Cyan-2-aminoalkylamino- und 3-Cyan-2-oxaalkyloxy-5-(pyrid-4-yl)-pyridine sind bisher nicht bekannt. Ebenso sind 5-Aryl-3-cyan-6-methyl-2-heteraalkylamino sowie
</DESCRIPTION>
<CLAIMS>
Claims for the Contracting States : BE, CH, DE, FR, GB, IT, LI, NL, SE
New 3-cyanopyridines of formula 

 
and their physiologically well-tolerated acid addition 

salts, characterized by the fact that 
R¹ represents hydroxyethylamino, 

bis(2-hydroxyethyl)amino, morpholino, 
2- or 3-hydroxypropylamino, 1-hydroxymethylpropylamino, 

4-hydroxybutylamino, 2-methoxyethylamino, 
2,2-dimethoxyethylamino, 2-(2-hydroxyethoxy)ethylamino, 

2-aminoethylamino, 3-diethylaminopropylamino, 
3-morpholinopropylamino, piperazino, 4-methylpiperazino, 

4-(2-hydroxyethyl)piperazino, 2-acetylaminoethylamino, 
4-acetylpiperazino, 4-propionylpiperazino, 

2-nicotinoylaminoethylamino, 2-methoxyethoxy, 
2-hydroxyethoxy, 2- or 3-hydroxypropoxy, 

2,3-dihydroxypropoxy, 2-(2-hydroxyethoxy)ethoxy, 
2-acetoxyethylamino, 3-acetoxypropylamino, 

2-acetoxyethoxy, 3-acetoxypropoxy, 
bis(2-acetoxyethyl)amino, 2,3-bisacetoxypropoxy, 

2-propionyloxyethylamino, 3-propionyloxypropylamino, 
3-propionyloxypropoxy, 2-nicotinoyloxyethylamino, 

3-nicotinoyloxypropylamino or 3-nicotinoyloxypropoxy, 
R² represents 4-pyridyl,
 
and R³ represents H or methyl. 
A process for the production of 3-cyanopyridines of 
Formula I, in which R¹, R² and R³ have the meaning  

 
mentioned in Claim 1, characterized by the fact that 

3-cynano-2-halopyridines of Formula II, in which R² and 
R³ have the above meaning 


 
are reacted 


a) with a compound of Formula
R¹ - H   III

 
if this is a hydroxyalkylamine, alkoxyalkylamine, 

morpholine, aminoalkylamine, piperazine or 
substituted piperazine, in which R¹ has the above 

meaning, to the 2-oxyalkylamino- or 
2-aminoalkylamino compounds

 
or 
b) with a compound of Formula
R¹ - H   III

 
if this is a di- or trihydroxyalkane or an 

alkoxyalkanol, in which R¹ has the above meaning, in 
presence of bases, such as anhydrous KOH or NaOH, or 

with the corresponding alkali metal alcoholates in 
the corresponding alcohol or in inert organic 

solvents to the 2-oxaalkoxy-compounds

 
or 
c) the 2-hydroxyalkylamino- or 2-aminoalkylamino-compounds 
of Formula I obtained according to a) are  

 
reacted with acid anhydrides or acid halides, 

preferably in presence of tertiary amines, to the 
corresponding 2-acyloxyalkylamino-, 

2-acylaminoalkylamino- or 2-acyloxyalkoxy-compounds 
of general Formula I 
 
and the compounds of Formula I are optionally converted 

with inorganic or organic acids to the corresponding acid 
addition salts. 
A process according to Claim 2a characterized by the fact 
that the reaction takes place in organic solvents such as 

alcohols, tertiary amines, pyridine, methoxyethanol, 
dioxane, dimethylformamide, dimethyl sulphoxide, 

acetonitrile, mixtures of these solvents and the 
heteraalkylamines themselves. 
A pharmaceutical agent characterized by the fact that it 
contains at least one compound of Formula I, according to 

Claim 1, and a physiologically well-tolerated carrier 
and/or a physiologically well-tolerated diluent. 
Pharmaceutical preparations characterized by the fact 
that they contain at least one compound of Formula I, 

according to Claim 1, and a suitable carrier. 
The use of compounds of Formula I, according to Claim 1, 
for the production of pharmaceutical preparations with 

cardiotonic, antiarrhythmic, vasodilator, bronchodilator 
and/or antiallergic effects. 
The use according to Claim 6, characterized by the fact 
that compounds of Formula I are used alone or in 

combination with each other, with other compounds with 
cardiotonic, antiarrhythmic, vasodilator, bronchodilator 

and/or antiallergic effects and/or with carriers.  
 
A process for the production of pharmaceutical 
preparations according to Claims 6 and 7, characterized 

by the fact that compounds of Formula 1 are used alone or 
in combination with each other or with other compounds 

with cardiotonic, antiarrhythmic, vasodilator, 
bronchodilator and/or antiallergic effects and/or with 

carriers. 
Claims for the following Contracting State : AT
A process for the production of new 3-cyanopyridines of 
formula 


 
and their physiologically well-tolerated acid addition 

salts, characterized by the fact that in Formula I 
R¹ represents hydroxyethylamino, 

bis(2-hydroxyethyl)amino, morpholino, 
2- or 3-hydroxypropylamino, 1-hydroxymethylpropylamino, 

4-hydroxybutylamino, 2-methoxyethylamino, 
2,2-dimethoxyethylamino, 2-(2-hydroxyethoxy)ethylamino, 

2-aminoethylamino, 3-diethylaminopropylamino, 
3-morpholinopropylamino, piperazino, 4-methylpiperazino, 

4-(2-hydroxyethyl)piperazino, 2-acetylaminoethylamino, 
4-acetylpiperazino, 4-propionylpiperazino, 

2-nicotinoylaminoethylamino, 2-methoxyethoxy, 
2-hydroxyethoxy, 2- or 3-hydroxypropoxy, 

2,3-dihydroxypropoxy, 2-(2-hydroxyethoxy)ethoxy, 
2-acetoxyethylamino, 3-acetoxypropylamino, 

2-acetoxyethoxy, 3-acetoxypropoxy, 
bis(2-acetoxyethyl)amino, 2,3-bisacetoxypropoxy, 

2-propionyloxyethylamino, 3-propionyloxypropylamino, 
3-propionyloxypropoxy, 2-nicotinoyloxyethylamino, 

3-nicotinoyloxypropylamino or 3-nicotinoyloxypropoxy, 
R² represents 4-pyridyl,
 
and R³ represents H or methyl.  

 
A process according to Claim 1, characterized by the fact 
that R¹ is set equal to oxaalkylamino for 

hydroxy-C₁₋₄-alkylamino, di(hydroxy-C₁₋₄-alkyl)amino, 
C₁₋₄-alkoxy-C₁₋₄-alkylamino, 

di(C₁₋₄-alkoxy-C₁₋₄-alkyl)amino, 
hydroxy-C₁₋₄-alkoxy-C₁₋₄-alkylamino or morpholino, 

that R¹ is set equal to aminoalkylamino for 
di(C₁₋₄-alkyl)amino-C₁₋₄-alkylamino, 

amino-C₁₋₄-alkylamino, morpholino-C₁₋₄-alkylamino or 
piperazino, which is optionally substituted by C₁₋₄-alkyl 

or hydroxy-C₁₋₄-alkyl, 
that R¹ is set equal to oxaalkoxy for hydroxy- or 

dihydroxy-C₁₋₄-alkoxy, C₁₋₄-alkoxy-C₁₋₄-alkoxy or 
hydroxy-C₁₋₄-alkoxy-C₁₋₄-alkoxy, 

that R¹ is set equal to acyloxyalkylamino for 
C₂₋₄-alkanoyloxy-C₁₋₄-alkylamino, 

di(C₂₋₄-alkanoyloxy-C₁₋₄-alkyl)amino or 
pyridylcarbonyloxy-C₁₋₄-alkylamino, 

that R¹ is set equal to acylaminoalkylamino for 
C₂₋₄-alkanoylamino-C₁₋₄-alkylamino or piperazino 

substituted by C₂₋₄-alkanoyl 
or that R¹ is set equal to acyloxyalkoxy for 

C₂₋₄-alkanoyloxy-C₁₋₄-alkoxy or 
pyridylcarbonyloxy-C₁₋₄-alkoxy. 
A process for the production of new 3-cyanopyridines of 
Formula I, in which R¹, R² and R³ have the meaning 

mentioned in Claims 1 or 2, characterized by the fact 
that 3-cyano-2-halopyridines of Formula II, 


  
 

in which R² and R³ have the meaning mentioned in Claims 1 
or 2, are reacted 


a) with hydroxyalkylamines, alkoxyalkylamines, 
morpholine, aminoalkylamines or piperazine or 

substituted piperazine to the 2-oxaalkylamino- or 
2-aminoalkylamino-compounds
 
or 
b) with di- or trihydroxyalkanes or alkoxyalkanols in 
presence of bases, such as anhydrous KOH or NaOH, or 

with the corresponding alkali metal alcoholates in 
the corresponding alcohol or in inert organic 

solvents to the 2-oxaalkoxy-compounds
 
or 
c) the 2-hydroxyalkylamino- or 2-aminoalkylamino-compounds 
from a) and the 2-hydroxyalkoxy compounds 

from b) are reacted with acid anhydrides or acid 
halides, preferably in presence of tertiary amines, 

to the 2-acyloxyalkylamino-, 2-acylaminoalkylamino-or 
2-acyloxyalkoxy-compounds and the compounds of 

Formula I are optionally converted with inorganic or 
organic acids to the corresponding acid addition 

salts. 
A process according to Claim 3, characterized by the fact 
that the reaction of the compounds of Formula II to the 

2-oxaalkylamino- or 2-aminoalkylamino-compounds is 
carried out in organic solvents, such as alcohols, 

tertiary amines, pyridine, methoxyethanol, dioxane, 
dimethylformamide, dimethyl sulphoxide, acetonitrile, 

mixtures of these solvents or the heteraalkylamines 
themselves. 
A pharmaceutical agent characterized by the fact that it 
contains at least one compound of Formula I, which is 

prepared in accordance with the process of one of Claims 
1 and 2, and a physiologically well-tolerated carrier 

and/or a physiologically well-tolerated diluent.  
 
Pharmaceutical preparations characterized by the fact 
that they contain at least one compound of Formula I, 

which is prepared according to the process of one of 
Claims 1 to 3, and a suitable carrier. 
The use of compounds of Formula I which are prepared in 
accordance with the process of one of Claims 1 and 2 for 

the production of pharmaceutical preparations with 
cardiotonic, antiarrhythmic, vasodilator, bronchodilator 

and/or antiallergic effects. 
The use according to Claim 7, characterized by the fact 
that compounds of Formula 1 are used alone or in 

combination with each other or with other compounds with 
cardiotonic, antiarrhythmic, vasodilator, bronchodilator 

and/or antiallergic effects and/or with carriers. 
A process for the production of pharmaceutical 
preparations according to Claims 7 and 8, characterized 

by the fact that compounds of Formula 1 are used alone or 
in combination with each other or with other compounds 

with cardiotonic, antiarrhythmic, vasodilator, 
bronchodilator and/or antiallergic effects and/or with 

carriers. 
</CLAIMS>
</TEXT>
</DOC>
